Featured Research

from universities, journals, and other organizations

Patient-controlled analgesia not as effective as epidural for labor pain

Date:
February 3, 2014
Source:
Society for Maternal-Fetal Medicine
Summary:
New findings suggest remifentanil patient controlled analgesia is not equivalent to epidural analgesia for pain, pain appreciation scores, and overall satisfaction in women who request for pain relief during labor.

In a study presented on Feb. 7 at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in New Orleans, researchers will report findings which suggest remifentanil patient controlled analgesia is not equivalent to epidural analgesia for pain, pain appreciation scores, and overall satisfaction in women who request for pain relief during labor.

Remifentanil patient controlled analgesia (RPCA) is a short-acting pain reliever, an opiate, similar to pethidine. It relieves pain rapidly, but also wears off very quickly, which makes it very suitable for administration through patient controlled analgesia. With RPCA the patient can give herself a dose of remifentanil intravenously every few minutes. Recent studies suggested that RCPA was equal to epidural analgesia (EA) in regards to satisfaction with pain relief, so this study, titled Remifentanil patient controlled analgesia versus epidural analgesia in labor; a randomized controlled equivalence trial set out to compare the effectiveness.

Pain appreciation was measured hourly on a visual analogue scale, and expressed as area under the curve (AUC). The AUC gives a time-weighted measure of total pain appreciation. It was calculated for the duration of labor and for the time that pain relief was administered. A higher AUC for pain appreciation represents higher satisfaction with pain relief.

For the study, 709 women were allocated to RPCA and 705 to EA. They were randomly chosen from healthy pregnant women who intended to deliver vaginally at 15 different hospitals in the Netherlands. Four hundred forty-seven women in the RPCA and 343 in the EA group received pain relief during labor. Among women allocated to RPCA, 344 received nothing but RPCA; in the EA group 295 received just EA. Thirteen percent of the women switched to EA after RPCA. The AUC for total pain appreciation during labor was 26.5 in the RPCA group versus 36.0 in the EA group.

"Recent studies suggest that remifentanil patient controlled analgesia (RPCA) is equivalent to epidural analgesia (EA) with respect to pain appreciation (satisfaction with pain relief). The aim of our study was to compare the effectiveness of RPCA with EA regarding pain appreciation," said Liv Freeman, M.D., one of the study's authors.

"The results of the study show that RPCA is not equivalent to EA with respect to pain appreciation, i.e. satisfaction with pain relief. Pain appreciation scores in women, who requested pain relief during labor, randomized to EA, are significantly better."


Story Source:

The above story is based on materials provided by Society for Maternal-Fetal Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Maternal-Fetal Medicine. "Patient-controlled analgesia not as effective as epidural for labor pain." ScienceDaily. ScienceDaily, 3 February 2014. <www.sciencedaily.com/releases/2014/02/140203084525.htm>.
Society for Maternal-Fetal Medicine. (2014, February 3). Patient-controlled analgesia not as effective as epidural for labor pain. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2014/02/140203084525.htm
Society for Maternal-Fetal Medicine. "Patient-controlled analgesia not as effective as epidural for labor pain." ScienceDaily. www.sciencedaily.com/releases/2014/02/140203084525.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins